Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionProduct description

Product information

37 evidence topics · 6 sources

American hospital formulary service (AHFS), or other drug classification

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on bevacizumab-vikg

No evidence found.

Effects of bevacizumab-vikg on other drugs

No evidence found.

Co-prescribed/Concomitant therapies

No evidence found.

Effect of bevacizumab-vikg on quality measures

No evidence found.